Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis.
OBJECTIVE
To compare the efficacy of antibiotics therapy alone with antibiotics and saccharomyces boulardii in treatment of acute amebiasis.


METHODS
In a double blind, random clinical trial on patients with acute intestinal amoebiasis, 57 adult patients with acute amoebiasis, diagnosed with clinical manifestations (acute mucous bloody diarrhea) and amebic trophozoites engulfing RBCs found in stool were enrolled in the study. Regimen 1 included metronidazole (750 mg Tid) and iodoquinol (630 mg Tid) for 10 days. Regimen 2 contained capsules of lyophilized saccharomyces boulardii (250 mg Tid) orally in addition to regimen 1. Patients were re-examined at two and four weeks after the treatment, and stool examination was performed at the end of week 4. Student's t-test, chi(2) and McNemar's tests were used for statistical analysis.


RESULTS
Three patients refused to participate. The other 54 patients were randomized to receive either regimen 1 or regimen 2 (Groups 1 and 2 respectively, each with 27 patients). The two groups were similar regarding their age, sex and clinical manifestations. In Group 1, diarrhea lasted 48.0+/-18.5 hours and in Group 2, 12.0+/-3.7 hours (P<0.0001). In Group 1, the durations of fever and abdominal pain were 24.0+/-8.8 and 24.0+/-7.3 hours and in Group 2 they were 12.0+/-5.3 and 12.0+/-3.2 hours, respectively (P<0.001). Duration of headache was similar in both groups. At week 4, amebic cysts were detected in 5 cases (18.5 %) of Group 1 but in none of the Group 2 (P<0.02).


CONCLUSIONS
Adding saccharomyces boulardii to antibiotics in the treatment of acute amebiasis seems to decrease the duration of clinical symptoms and cyst passage.
Mansour-Ghanaei
Fariborz
F
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Sardar-e-jangle Ave, Razi Hospital, Rasht 41448-95655, Iran. ghanaei@gums.ac.ir
Dehbashi
Najaf
N
Yazdanparast
Kamyar
K
Shafaghi
Afshin
A
D000208:Acute Disease; D000284:Administration, Oral; D000562:Amebiasis / Q000628:therapy*; D000563:Amebicides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002214:Capsules; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006801:Humans; D004103:Iodoquinol / Q000627:therapeutic use*; D008795:Metronidazole / Q000627:therapeutic use*; D019936:Probiotics / Q000008:administration & dosage*; D012440:Saccharomyces; D016896:Treatment Outcome
D000563:Amebicides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002214:Capsules; D008795:Metronidazole; D004103:Iodoquinol